On May 22, 2026, Polpharma Biologics announced that it had entered into an exclusive licensing agreement with Tuteur to commercialize a biosimilar targeting autoimmune diseases across Latin America, excluding Brazil. The parties did not disclose which specific biosimilar is covered by the license.
Under the agreement, Polpharma Biologics will retain full responsibility for development and manufacturing of the biosimilar, while Tuteur will be responsible for commercialization, marketing, and distribution in the licensed territories.